Literature DB >> 12146020

Criteria for organized cervical screening programs. Special emphasis on The Netherlands program.

Antonius G J M Hanselaar1.   

Abstract

Based on the criteria of Wilson and Jungner and experiences in the population-based organized cervical screening program in the Netherlands, conditions for efficient and effective population screening for cervical cancer are described. The purpose of this paper is to determine if these criteria are met for cervical cancer screening and to give recommendations for improvement. Cervical cancer is still an important health problem; the present incidence reflects both background risk and screening activity during previous decades. A positive effect of screening is reached because of the long development time of the disease and the ability of the Pap smear test to detect precancer and early, symptomatic disease. Considerable reduction in the incidence and mortality of cervical cancers can be reached if all women attend and all detected lesions are adequately followed up. Common terminology and classification criteria for histology and cytology should be used. Whether newly developed techniques that may improve or replace cytology can be used in screening programs should be a multidisciplinary decision after clinical trials have given evidence-based information on the performance, cost-effectiveness and need of these techniques. When cervical cancer screening is undertaken, it should be offered in organized programs at the medical level closest to the patients, the general practitioner. High compliance is the most important factor in reducing cervical cancer incidence. Quality control and assurance must be performed at all levels. In the case of limited resources, the program should use a five-year interval and concentrate on the age range 25-60 years, with special attention to women who have never been screened or were screened > 10 years previously. Evaluation of medical and organizational aspects is mandatory. Cooperation between all involved parties is a prerequisite of creating a successful screening program.

Entities:  

Mesh:

Year:  2002        PMID: 12146020     DOI: 10.1159/000326965

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  9 in total

1.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush.

Authors:  Antoinette A T P Brink; Chris J L M Meijer; Maarten A H M Wiegerinck; Thedoor E Nieboer; Roy F P M Kruitwagen; Folkert van Kemenade; Nathalie Fransen Daalmeijer; Albertus T Hesselink; Johannes Berkhof; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.

Authors:  Roosmarijn Luttmer; Maaike G Dijkstra; Peter J F Snijders; Johannes Berkhof; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; René H M Verheijen; W Abraham Ter Harmsel; W Marchien van Baal; Peppino G C M Graziosi; Wim G V Quint; Johan W M Spruijt; Dorenda K E van Dijken; Daniëlle A M Heideman; Chris J L M Meijer
Journal:  Mod Pathol       Date:  2016-05-06       Impact factor: 7.842

4.  HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study.

Authors:  Murat Gök; Daniëlle A M Heideman; Folkert J van Kemenade; Johannes Berkhof; Lawrence Rozendaal; Johan W M Spruyt; Feja Voorhorst; Jeroen A M Beliën; Milena Babovic; Peter J F Snijders; Chris J L M Meijer
Journal:  BMJ       Date:  2010-03-11

5.  Consolidated principles for screening based on a systematic review and consensus process.

Authors:  Mark J Dobrow; Victoria Hagens; Roger Chafe; Terrence Sullivan; Linda Rabeneck
Journal:  CMAJ       Date:  2018-04-09       Impact factor: 8.262

6.  HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.

Authors:  D C Rijkaart; J Berkhof; F J van Kemenade; V M H Coupe; L Rozendaal; D A M Heideman; R H M Verheijen; S Bulk; W Verweij; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2012-01-17       Impact factor: 7.640

7.  Role of FAM19A4/miR124-2 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study.

Authors:  Wieke W Kremer; Johannes Berkhof; Maaike Cg Bleeker; Daniëlle Am Heideman; Nienke E van Trommel; Marchien W van Baal; Harold R Verhoeve; Chris Jlm Meijer; Gemma G Kenter
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

8.  DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Authors:  A Boers; R P Bosgraaf; R W van Leeuwen; E Schuuring; D A M Heideman; L F A G Massuger; V M J Verhoef; J Bulten; W J G Melchers; A G J van der Zee; R L M Bekkers; G B A Wisman
Journal:  Br J Cancer       Date:  2014-07-17       Impact factor: 7.640

9.  Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.

Authors:  M H Uijterwaal; B I Witte; F J Van Kemenade; D Rijkaart; R Ridder; J Berkhof; G A M A Balfoort-van der Meij; M C G Bleeker; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.